Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Upstream Bio, Inc. plans to raise $100 million through an IPO to advance its promising Phase 2 drug candidate, verekitug, for severe asthma and chronic rhinosinusitis. The company is well-capitalized ...
Hosted on MSN
Upstream Bio Reports Progress in Respiratory Trials
Upstream Bio, Inc. ( (UPB)) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors. Upstream Bio, Inc. is a clinical-stage biotechnology ...
Upstream Bio, Inc. ( (UPB)) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors. Upstream Bio, Inc., a clinical-stage biotechnology ...
Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 8, Upstream Bio announced that the first patient had been dosed in a Phase 2 ...
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback